

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/926,807	. 03/19/2002	Jacobus Johannes Marion Meyer	742439-3	4847	
22204	7590 05/14/2003				
NIXON PEABODY, LLP 8180 GREENSBORO DRIVE SUITE 800			EXAMINER		
			WEDDINGTON, KEVIN E		
MCLEAN,	VA 22102		ART UNIT	PAPER NUMBER	
			1614	'n	
		•	DATE MAILED: 05/14/2003	12	

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. 09/926,807

Applicant(s)

Meyer et al.

Examiner

Kevin E. Weddington

Art Unit 1614



	The MAILING DATE of this communication appears	n the cover si	eet with	the c rrespondence address	
Period 1	for Reply				
THE I	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.  Identifying the state of time may be evailable under the provisions of 37 CFR 1.136 (a). In read the of this communication.			<del>-</del>	
- If the property - If NO property - If NO property - If NO property - If the proper	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply as to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nd will expire SIX (6 e application to bec	) MONTHS f	rom the mailing date of this communication. ONED (35 U.S.C. § 133).	
Status					
1) 💢	Responsive to communication(s) filed on Jan 21, 20	003		· .	
2a) 🗌	This action is <b>FINAL</b> . 2b) ☑ This acti	ion is non-fina	l.		
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under <i>Ex pair</i>	*		·	
Disposi	tion of Claims				
4) 💢	Claim(s) <u>12-21</u>	-		is/are pending in the application.	
4	a) Of the above, claim(s) <u>12-17</u>			is/are withdrawn from consideration.	
5) 🗆	Claim(s)			is/are allowed.	
6) 💢	Claim(s) 18-21			is/are rejected.	
7) 🗆	Claim(s)			is/are objected to.	
8) 🗆	Claims	ar	e subject	to restriction and/or election requirement.	
Applica	ition Papers				
9) 🗆	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	a) 🗆 accept	ed or b)	objected to by the Examiner.	
	Applicant may not request that any objection to the de	rawing(s) be h	eld in abe	yance. See 37 CFR 1.85(a).	
11)	The proposed drawing correction filed on	is	s: a)□ a	approved b) $\square$ disapproved by the Examiner.	
	If approved, corrected drawings are required in reply t	o this Office a	ction.		
12)	The oath or declaration is objected to by the Exami	ner.			
Priority	under 35 U.S.C. §§ 119 and 120				
13)□	Acknowledgement is made of a claim for foreign pr	iority under 3	5 U.S.C.	§ 119(a)-(d) or (f).	
a)[	☐ All b)☐ Some* c)☐ None of:				
	1. $\square$ Certified copies of the priority documents have	e been receiv	ed.		
	2.   Certified copies of the priority documents have	e been receiv	ed in Ap <sub>l</sub>	plication No	
	3. Copies of the certified copies of the priority do application from the International Burea				
*S	ee the attached detailed Office action for a list of the	e certified cop	ies not r	eceived.	
14)	Acknowledgement is made of a claim for domestic	priority under	35 U.S.	C. § 119(e).	
a) [					
15) 📙	Acknowledgement is made of a claim for domestic	priority under	35 U.S.	C. §§ 120 and/or 121.	
Attachm					
	otice of References Cited (PTO-892)			O-413) Paper No(s).	
_	2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  5) Notice of Informal Patent Application (PTO-152)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).				
5, ∐ in	iornation previous otatement(s) (F10-1443) raper No(s).	or Li other.			

Application/Control Number: 09/926,807

Art Unit: 1614

Claims 12-21 are presented for examination.

Applicants' election filed January 21, 2003 in response to the restriction requirement of December 20, 2002 has been received and entered. The applicants elected the invention described in claims 18-21 (Group III).

Claims 12-17 are withdrawn from consideration as being drawn to the non-elected invention 37 CFR (1.142(b)).

### Claim Rejections ~ 35 U.S.C. § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 18-20 are rejected under 35 U.S.C. 102(a) as being anticipated by Vichkanova et al. (R).

Vichkanova et al. teach a study of antimicrobial activity of naphthoquinones against Mycobacterium tuberculosis. Note the naphthoquinone used in the reference is plumbagin (methyljuglone). Clearly, the cited reference anticipates the application instant invention, therefore, the instant invention is unpatentable.

Claims 18-20 are not allowed.

Application/Control Number: 09/926,807 Page 3

**Art Unit: 1614** 

## Claim Rejections - 35 U.S.C. § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 21 is rejected under 35 U.S.C. 103(a) as being unpatentable over

Vichkanova et al. (R).

Vichkanova et al. was discussed above <u>supra</u> for the antimicrobial activity of naphthoquinones.

The instant invention differs from the cited reference in that the cited reference does not teach the instant invention is administered orally, intravenously, intramuscularly or transdermally. However, one skilled in the art would have administered the instant invention to any host or subject by any mode of administration since the various of modes of administration are routinely used in the pharmaceutical art.

Claim 21 is not allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner K. Weddington whose telephone number is (703) 308-1235.

Art Unit: 1614

Kevin E. Weddington
Primary Examiner
Art Unit 1614

K. Weddington

May 12, 2003